In the United States, treatment options for MDS vary depending on the specific subtype and risk level of the disease. For lower risk MDS, the standard first line treatment is erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa. These drugs work to stimulate the bone marrow to produce more red blood cells and help reduce the need for blood transfusions https://www.coherentmarketinsights.com/market-insight/us-europe-and-china-myelodysplastic-syndrome-treatment-market-4513